REPORT Happy Friday! This weekend is daylight saving time, I’d tell you to change your clocks but I’m guessing most of us ...

Emergen Research Logo The global Generic Drug Market size was USD 360.84 Billion in 2022 and is expected to register a rapid revenue CAGR o ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ingenuity but for their potential to radically improve human lives. One such ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

Morgan Stanley analyst Terence Flynn notes that Novo Nordisk (NVO) reported CagriSema Phase 3 data in type two diabetes demonstrating weight ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Late-breaking results from Eli Lilly and Company (NYSE ... least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which ...

Data in diabetes suggests tirzepatide could be a disruptive force in the diabetes market, as Lilly tries to position it as a replacement for its $5 billion once-weekly GLP-1 drug Trulicity ...

Novo Nordisk will slash the price of its blockbuster weight-loss drug Wegovy for cash-paying patients, after American rival ...

Judy Kurtz chats with The Hill’s congressional reporter Mychael Schnell about President Trump saying he wants to “help” Mexico and Canada with his delay of some tariffs against Canada and Mexico until ...